Merck's raltegravir combination beats efavirenz combo in treatment-naive HIV
This article was originally published in Scrip
Executive Summary
Merck has presented previously unreported data showing that combination HIV therapy containing its integrase inhibitor, Isentress (raltegravir), confers better efficacy than that containing efavirenz (Bristol-Myers Squibb's Sustiva) in treatment-naïve adult patients.